Fig. 1From: PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinomaPRIME-HCC study objectives and timeline (original figure, no copyright permission required; Created with BioRender.com)Back to article page